SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes
Status:
Not yet recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
Study to assess the effects of weekly subcutaneous administration of the GLP1-RA semaglutide
2.4mg on kidney function parameters in obese/overweight individuals at high risk of CKD
progression.